BiotechTube

Atogepant 60 mg + Propranolol 160 mg + Topiramate 100 mg

ApprovedRecruiting
1 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Migraine

Conditions

Migraine

Trial Timeline

Jul 9, 2025 → Dec 1, 2029

NCT ID
NCT06972056

About Atogepant 60 mg + Propranolol 160 mg + Topiramate 100 mg

Atogepant 60 mg + Propranolol 160 mg + Topiramate 100 mg is a approved stage product being developed by AbbVie for Migraine. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06972056. Target conditions include Migraine.

What happened to similar drugs?

20 of 20 similar drugs in Migraine were approved

Approved (20) Terminated (1) Active (0)
✅Galcanezumab + ErenumabEli LillyApproved
✅Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
✅Emgality 120 MG in 1 ML Prefilled SyringeEli LillyApproved
✅tramadol HCl/acetaminophenJohnson & JohnsonApproved
✅topiramate; almotriptan malateJohnson & JohnsonApproved
✅Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]AbbVieApproved
✅Atogepant + UbrogepantAbbVieApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06972056ApprovedRecruiting

Competing Products

20 competing products in Migraine

See all competitors
ProductCompanyStageHype Score
DFN-11Dr. Reddy's LaboratoriesPhase 2
32
DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
37
DFN-15 (fasted) + DFN-15 (fed) + Comparator Celebrex® (fed)Dr. Reddy's LaboratoriesPhase 1
26
DFN-11Dr. Reddy's LaboratoriesPhase 3
37
DFN-02Dr. Reddy's LaboratoriesPhase 3
37
DFN-15 Dose A (treatment A) + DFN-15 Dose B (treatment B)Dr. Reddy's LaboratoriesPhase 2
32
DFN-15Dr. Reddy's LaboratoriesPhase 2
32
ABP-450AEON BiopharmaPhase 2
17
Lasmiditan + PlaceboEli LillyPhase 3
40
Placebo + LY2300559Eli LillyPhase 2
27
lasmiditan 200 mg + Sumatriptan + matching placeboEli LillyPhase 1
29
ABP-450 + PlaceboAEON BiopharmaPhase 2
25
Lasmiditan + PlaceboEli LillyPhase 2
35
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
17
Galcanezumab + ErenumabEli LillyApproved
43
Aricept (donepezil hydrochloride)EisaiPhase 2
35
E2007EisaiPhase 2
35
Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
43
Galcanezumab + PlaceboEli LillyPhase 3
40
Lasmiditan + PlaceboEli LillyPhase 2
35